Search
Ampreloxetine
go.drugbank.com/drugs/DB15348InvestigationalAmpreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).
Lorukafusp alfa
go.drugbank.com/drugs/DB15443InvestigationalLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Fluzoparib
go.drugbank.com/drugs/DB15637InvestigationalFluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
Rogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Inetetamab
go.drugbank.com/drugs/DB17457InvestigationalIt differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
HLX70
go.drugbank.com/drugs/DB16509Investigationalin healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.
(4R)-limonene
go.drugbank.com/drugs/DB08921Investigationalin perfumery. … Limonene is common in cosmetic products.
Synonyms: (4R)-1-methyl-4-isopropenylcyclohex-1-eneSelenocysteine
go.drugbank.com/drugs/DB02345InvestigationalA naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes.
Paquinimod
go.drugbank.com/drugs/DB13118InvestigationalThe disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.
Tyramine
go.drugbank.com/drugs/DB08841InvestigationalNutraceuticalThere have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.